drugset

drugset / Trial / NCT04232553

A Long-term Extension Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease

NCT04232553 ↗

Phase 3 Active not recruiting 996 enrolled Eli Lilly and Company

Non-randomizedParallel-groupOpen-labelTreatment

Summary

The reason for this study is to determine the long-term efficacy and safety of the study drug mirikizumab in participants with Crohn's disease.

Timeline

Start: 2020-06-22
Primary completion: 2024-11-28
Completion: 2027-04

Publications

Sands BE, Barnes EL, D'Haens G, Hisamatsu T, Regueiro M, Kelly CR, Laharie D, Hozak RR, Yu G, Gandhi R A, Lopes MU, Durand F, Protic M, Moses RE, Vermeire S. Mirikizumab Long-Term Efficacy and Safety in Patients With Crohn's Disease: Results From the VIVID-2 Open-Label Extension Trial. Clin Gastroenterol Hepatol. 2026 Mar 5:S1542-3565(26)00155-2. doi: 10.1016/j.cgh.2026.01.049. Online ahead of print.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Mirikizumab	Monoclonal antibody	300 mg	Subcutaneous

Indications